RxDoctor Payments Data

Daniel Jasko, MD

Family Medicine · Riverview, FLNPI 1043260078

Payments from drug & device makers

$535in general payments, 2019–2025

Across 18 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$199
  • GSK$122
  • Exact Sciences$104
  • Johnson & Johnson$87
  • Amarin Pharma, Inc.$23

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott10$199
GSK1$122
Exact Sciences5$104
Johnson & Johnson1$87
Amarin Pharma, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$535 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$178,203
Medicare patients
297
Services billed
2,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$175,124
JardianceEmpagliflozin116$136,869
TrulicityDulaglutide70$94,085
MounjaroTirzepatide61$78,025
EliquisApixaban47$53,555
XareltoRivaroxaban23$34,408
Repatha SureclickEvolocumab17$17,559
JanuviaSitagliptin Phosphate13$14,521
Tresiba Flextouch U-200Insulin Degludec11$13,498
FarxigaDapagliflozin Propanediol17$13,004
Rosuvastatin Calcium430$7,114
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,959
SynthroidLevothyroxine Sodium51$5,292
Losartan Potassium501$5,019
Atorvastatin Calcium393$4,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$87$34,40823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →